Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MultiStem

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Treatment evaluation of acute stroke for using in regenerative cell elements (TREASURE) trial: Rationale and design
Rationale MultiStem® (HLM051) is one of the promising allogenic cell products for acute ischemic stroke with strong evidence. A… Expand
Is this relevant?
2016
2016
Adult adherent cell therapy for ischemic stroke: clinical results and development experience using MultiStem.
I schemic stroke is caused by a blockage of blood flow to the brain. A leading cause of death and disability globally, each year… Expand
  • table 1
  • table 2
Is this relevant?
2016
2016
Clinical-Grade Human Multipotent Adult Progenitor Cells Block CD8+ Cytotoxic T Lymphocytes.
: MultiStem cells are clinical-grade multipotent adult bone marrow-derived progenitor cells (MAPCs), with extensive replication… Expand
Is this relevant?
2016
2016
Abstract 71: Final Results of the B01-02 Phase 2 Trial Testing the Safety and Efficacy of MultiStem® in Treatment of Ischemic Stroke
Introduction: MultiStem is an adult, adherent, stem cell product, having shown safety and efficacy in other clinical indications… Expand
Is this relevant?
2014
2014
A Double-Blind Placebo-Controlled Clinical Evaluation of Multistem for the Treatment of Ischemic Stroke
Background There is growing interest in neurorestorative and reparative therapies after acute stroke. MultiStem® is an allogeneic… Expand
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: phase I clinical study.
RATIONALE MultiStem is an allogeneic bone marrow-derived adherent adult stem cell product that has shown efficacy in preclinical… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2011
2011
Company profile: Athersys.
Athersys (Nasdaq: ATHX) is a biopharmaceutical company engaged in the discovery and development of novel therapies designed to… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
Mouse MAPC-mediated immunomodulation: Cell-line dependent variation.
Adoptive therapy with mesenchymal stem cells (MSC) is being developed as a promising approach in the treatment of graft-vs-host… Expand
Is this relevant?
2009
2009
Global Characterization and Genomic Stability of Human MultiStem, A Multipotent Adult Progenitor Cell.
The therapeutic benefits of adult adherent stem cells are currently being investigated in clinical trials for a variety of… Expand
Is this relevant?
2004
2004
Incidence, size and spatial structure of clones in second-growth stands of coast redwood, Sequoia sempervirens (Cupressaceae).
The ecology and evolutionary potential of coast redwood (Sequoia sempervirens) is significantly influenced by the important role… Expand
  • figure I
  • table I
  • table 2
  • figure 2
  • figure 3
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE